Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Scientific Research Center, East China Institute of Digital Medical Engineering, Shangrao, China.
Bioengineered. 2021 Dec;12(1):4016-4031. doi: 10.1080/21655979.2021.1951927.
Epithelial-mesenchymal transition (EMT)-related long non-coding RNAs (lncRNAs) may be exploited as potential therapeutic targets in gliomas. However, the prognostic value of EMT-related lncRNAs in gliomas is unclear. We obtained lncRNAs from The Cancer Genome Atlas and constructed EMT-related lncRNA co-expression networks to identify EMT-related lncRNAs. The Chinese Glioma Genome Atlas (CGGA) was used for validation. Gene set enrichment and principal component analyses were used for functional annotation. The EMT-lncRNA co-expression networks were constructed. A real-time quantitative polymerase chain reaction assay was performed to validate the bioinformatics results. A nine-EMT-related lncRNAs (HAR1A, LINC00641, LINC00900, MIR210HG, MIR22HG, PVT1, SLC25A21-AS1, SNAI3-AS1, and SNHG18) signature was identified in patients with glioma. Patients in the low-risk group had a longer overall survival (OS) than those in the high-risk group (P < 0.0001). Additionally, patients in the high-risk group showed no deletion of chromosomal arms 1p and/or 19q, isocitrate dehydrogenase wild type, and higher World Health Organization grade. Moreover, the signature was identified as an independent factor and was significantly associated with OS (P = 0.041, hazard ratio = 1.806). These findings were further validated using the CGGA dataset. The low- and high-risk groups showed different EMT statuses based on principal component analysis. To study the regulatory function of lncRNAs, a lncRNA-mediated ceRNA network was constructed, which showed that complex interactions of lncRNA-miRNA-mRNA may be a potential cause of EMT progression in gliomas. This study showed that the nine-EMT-related lncRNA signature has a prognostic value in gliomas.
上皮-间充质转化(EMT)相关的长链非编码 RNA(lncRNA)可能成为胶质瘤潜在的治疗靶点。然而,EMT 相关 lncRNA 在胶质瘤中的预后价值尚不清楚。我们从癌症基因组图谱(TCGA)中获取 lncRNA,并构建 EMT 相关 lncRNA 共表达网络来识别 EMT 相关 lncRNA。中国脑胶质瘤基因组图谱(CGGA)用于验证。基因集富集和主成分分析用于功能注释。构建 EMT-lncRNA 共表达网络。实时定量聚合酶链反应(qPCR)实验验证生物信息学结果。鉴定出胶质瘤患者存在 9 个 EMT 相关 lncRNAs(HAR1A、LINC00641、LINC00900、MIR210HG、MIR22HG、PVT1、SLC25A21-AS1、SNAI3-AS1 和 SNHG18)的特征。低危组患者的总生存期(OS)明显长于高危组(P<0.0001)。此外,高危组患者未发生 1p 和/或 19q 染色体臂缺失、异柠檬酸脱氢酶野生型和较高的世界卫生组织(WHO)分级。此外,该特征被确定为独立因素,与 OS 显著相关(P=0.041,风险比=1.806)。这些发现使用 CGGA 数据集进一步验证。基于主成分分析,低危组和高危组表现出不同的 EMT 状态。为了研究 lncRNA 的调控功能,构建了 lncRNA 介导的 ceRNA 网络,表明 lncRNA-miRNA-mRNA 的复杂相互作用可能是胶质瘤 EMT 进展的潜在原因。本研究表明,9 个 EMT 相关 lncRNA 特征在胶质瘤中具有预后价值。